Xvivo Perfusion Dirección

Dirección controles de criterios 3/4

Xvivo Perfusion's El consejero delegado es Christoffer Rosenblad , nombrado en Jan 2022, tiene un mandato de 2.08 años. posee directamente 0.18% de las acciones de la empresa, con un valor de SEK16.16M . La antigüedad media del equipo directivo y del consejo de administración es de 3.3 años y 3.3 años, respectivamente.

Información clave

Christoffer Rosenblad

Chief Executive Officer (CEO)

kr5.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.3yrs
Participación del CEO	0.2%
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Christoffer Rosenblad (48 yo)

2.3yrs

Permanencia

kr5,031,000

Compensación

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christoffer Rosenblad	Chief Executive Officer	2.3yrs	kr5.03m	0.18% SEK 18.2m
Kristoffer Nordstrom	Chief Financial Officer	3.4yrs	sin datos	0.0085% SEK 874.1k
Lena Hagman	Chief Operating Officer	1.3yrs	sin datos	0.0063% SEK 656.1k
Ylva Vihoj	Global Human Resources Director	1.3yrs	sin datos	sin datos
Magnus Nilsson	Senior Advisor	3.8yrs	kr1.62m	sin datos
Andreas Wallinder	Chief Medical Officer	3.6yrs	sin datos	0.011% SEK 1.1m
Johan Holmstrom	Chief Commercial Officer	3.6yrs	sin datos	sin datos

3.4yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: 0RKLEl equipo directivo de la empresa se considera experimentado (3.1 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gosta Johannesson	Chairman of the Board	11.3yrs	kr440.00k	0.015% SEK 1.5m
Lars Henriksson	Independent Director	3.5yrs	sin datos	0.0060% SEK 623.0k
Erik Stromqvist	Independent Director	less than a year	sin datos	sin datos
Camilla Oberg	Independent Director	7.9yrs	kr130.00k	0.0032% SEK 327.5k
Lena Hoglund	Independent Director	3.5yrs	sin datos	0.0041% SEK 426.7k
Goran Dellgren	Independent Director	2yrs	sin datos	sin datos

3.5yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0RKL se considera experimentada (3.2 años de antigüedad promedio).

Xvivo Perfusion Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chairman of the Board recently bought kr281k worth of stock

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Independent Director recently bought kr107k worth of stock

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

Recent updates

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Chairman of the Board recently bought kr281k worth of stock

Full year 2023 earnings released: EPS: kr3.07 (vs kr0.62 in FY 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

New minor risk - Profit margin trend

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 21% undervalued

New minor risk - Shareholder dilution

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Second quarter 2023 earnings released: EPS: kr0.23 (vs kr0.26 in 2Q 2022)

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

New minor risk - Share price stability

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Independent Director recently bought kr107k worth of stock

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Now 20% undervalued

Now 20% undervalued

Now 20% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Xvivo Perfusion AB (Publ) Presents Positive Results from the Australian & New Zealand Heart Preservation Study

Chairman of the Board recently bought kr201k worth of stock

Third quarter 2022 earnings released: EPS: kr0.18 (vs kr0.039 loss in 3Q 2021)

Xvivo Perfusion AB (publ) Announces CEO Changes

XVIVO Perfusion AB Receives Breakthrough Device Designation Grant from the FDA for the Liver Assist Device

Xvivo Perfusion AB (publ) (OM:XVIVO) signed an agreement to acquire Machine and perfusion business from Avionord Srl for €12 million.

Second quarter 2022 earnings released: EPS: kr0.26 (vs kr0.31 loss in 2Q 2021)

First quarter 2022 earnings released: EPS: kr0.16 (vs kr0.21 in 1Q 2021)

Full year 2021 earnings released: EPS: kr0.28 (vs kr1.61 loss in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Xvivo Perfusion AB (publ) to Report Q1, 2022 Results on Apr 25, 2022

President & CEO recently bought kr141k worth of stock

President & CEO recently bought kr105k worth of stock

Third quarter 2021 earnings released: kr0.039 loss per share (vs kr0.51 loss in 3Q 2020)

President & CEO recently bought kr150k worth of stock

COO & Deputy CEO recently sold kr1.6m worth of stock

Second quarter 2021 earnings released: kr0.31 loss per share (vs kr0.60 loss in 2Q 2020)

First quarter 2021 earnings released: EPS kr0.21 (vs kr0.25 in 1Q 2020)

Full year 2020 earnings released: kr1.61 loss per share (vs kr0.19 profit in FY 2019)

Revenue misses expectations

New 90-day low: kr106

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

Xvivo Perfusion AB (publ) Announces Board Changes

Xvivo Perfusion AB (publ) (OM:XVIVO) entered into agreement to acquire Organ Assist BV for €24 million.

Xvivo Perfusion AB (Publ) Announces Management Changes

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad